Drug intelligence / Profile preview

BCM-5031

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

BCM-5031 is an autologous cell therapy product comprising dendritic cells (DC) and cytokine-induced killer (CIK) cells. Developed by ImmuneCyte Life Sciences, it is intended for the treatment of solid tumors, specifically targeting micro-metastatic disease in the adjuvant setting following surgical resection. The mechanism of action involves the synergistic effect of dendritic cells, which enhance the presentation of tumor antigens to the immune system, and CIK cells, which exhibit potent, non-major histocompatibility complex (MHC)-restricted cytotoxic activity against malignant cells. This dual approach is designed to eradicate residual cancer cells and reduce the risk of recurrence.

Beyond the preview

Go deeper on BCM-5031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCM-5031.

Explore the full profile